Search

Displaying results 5421 - 5430 of 8196 in total
  1. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.

    Synonyms: p-AminopyridineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 Substrates
  2. Drug

    Teduglutide

    go.drugbank.com/drugs/DB08900
    ApprovedInvestigational

    Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (a...

  3. Drug

    Gefitinib

    go.drugbank.com/drugs/DB00317
    ApprovedInvestigational

    Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is ma...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  4. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    Defactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases. FAK is important for the integrin-...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inducers
  5. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    Zongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2). It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pa...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. Developed to circumvent the adherence barriers and strict administration requirements of peptide-based GLP-1 therapies, its small-molecu...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  7. Drug

    DTX-101

    go.drugbank.com/drugs/DB17699
    Investigational

    DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene.

  8. Drug

    Tesevatinib

    go.drugbank.com/drugs/DB11973
    Investigational

    In addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis.

  9. Drug

    Sedecamycin

    go.drugbank.com/drugs/DB21342
    Experimental

    Sedecamycin has a monoisotopic molecular weight of 501.24 Da.

  10. Drug

    Cianopramine

    go.drugbank.com/drugs/DB19470
    Experimental

    Cianopramine has a monoisotopic molecular weight of 305.19 Da.